3rd Conf Retro and Opportun Infect. 1996 Jan 28-Feb 1;:174. Unique
Although there has been considerable progress in the treatment and
prevention of Pneumocystis carinii pneumonia (PCP) in patients with
AIDS, victory over this opportunistic infection has not been declared
yet. Data from prospective clinical trials and from observational
studies suggest that as many as 20% of patients with advanced HIV
infection still develop PCP in spite of receiving standard recommended
prophylaxis. This is mainly seen in patients unable to tolerate
trimethoprim-sulfamethoxazole (TMP-SMZ) suggesting that finding better
alternatives should become a priority, the basic nature of TMP-SMZ
intolerance is poorly understood and strategies to overcome it and
improve tolerance would greatly benefit from increased information as to
its cause. However, TMP-SMZ failure also occurs and the possibility of
resistance exists and has not yet been adequately addressed. In fact,
there is much to be learned about the pathogenesis of PCPd that may help
guide future therapeutic efforts. For toxoplasmosis, better therapy and
diagnostic tests are needed. For the enteric protozoan pathogens the
situation is even more daunting, although newer investigative strategies
offer some promise.
Acquired Immunodeficiency Syndrome/*COMPLICATIONS Human Pneumonia,
Pneumocystis carinii/COMPLICATIONS/*DRUG THERAPY/ PREVENTION & CONTROL
Protozoan Infections/COMPLICATIONS/DRUG THERAPY/PREVENTION & CONTROL
Trimethoprim-Sulfamethoxazole Combination/THERAPEUTIC USE ABSTRACT